Sugi Predict

Sugi Predict / Compounds / SCHEMBL874164

SCHEMBL874164

SCHEMBL874164

COc1cc2nc(-c3cccc(-c4ccccc4)c3)[nH]c(=O)c2cc1OC

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GUSB P08236 3/20 0.65
▸ CYP1A1 P04798 2/20 0.58
▸ CYP1B1 Q16678 2/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ TNKS O95271 1/20 0.57
▸ TNKS2 Q9H2K2 1/20 0.57
▸ PARP2 Q9UGN5 1/20 0.57
▸ CDK4 P11802 1/20 0.57
▸ CCND1 P24385 1/20 0.57
▸ TUBB4A P04350 1/20 0.56
▸ TUBB P07437 1/20 0.56
▸ TUBA3C P0DPH7 1/20 0.56
▸ TUBA1B P68363 1/20 0.56
▸ TUBA4A P68366 1/20 0.56
▸ TUBB4B P68371 1/20 0.56
▸ TUBB3 Q13509 1/20 0.56
▸ TUBB2A Q13885 1/20 0.56
▸ TUBB8 Q3ZCM7 1/20 0.56
▸ TUBA3E Q6PEY2 1/20 0.56
▸ TUBA1A Q71U36 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874165 0.92 GUSB (0.68) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL259473 0.92 GUSB (0.67) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL874334 0.91 GUSB (0.56) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL878156 0.90 GUSB (0.66) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL874166 0.86 GUSB (0.60) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL11919793 0.84 GUSB (0.55) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL874335 0.83 GUSB (0.58) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL874404 0.83 GUSB (0.61) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL878157 0.82 GUSB (0.69) GUSBCYP1A1CYP1B1CYP1A2TNKS
SCHEMBL873763 0.82 GUSB (0.67) GUSBTNKSTNKS2PARP2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-9440961-B2 Rho-kinase inhibitors and method of preparation SURFACE LOGIX, INC. (US) 2016-09-13 — — US disclosed
WO-2012040499-A2 METABOLIC INHIBITORS SURFACE LOGIX, INC. (US) 2012-03-29 — — WO disclosed
EP-2406236-A1 RHO KINASE INHIBITORS Surface Logix, Inc. (US) 2012-01-18 — — EP disclosed
WO-2010104851-A1 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2010-09-16 — — WO disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
EP-1865958-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS Surface Logix, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006105081-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 GUSB 895/4885CYP1A1 309/4885CYP1B1 164/4885
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 GUSB 895/4885CYP1A1 309/4885CYP1B1 164/4885
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 GUSB 895/4885CYP1A1 309/4885CYP1B1 164/4885
US-20100144707-A1 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 GUSB 895/4885CYP1A1 309/4885CYP1B1 164/4885
US-10570123-B2 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 GUSB 895/4885CYP1A1 309/4885CYP1B1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.